Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $20.00 and last traded at $19.55, with a volume of 120489 shares. The stock had previously closed at $18.42.
Wall Street Analyst Weigh In
TYRA has been the subject of a number of recent analyst reports. Bank of America downgraded Tyra Biosciences from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $25.00 to $15.00 in a report on Friday, December 15th. Wedbush restated an “outperform” rating and issued a $27.00 target price on shares of Tyra Biosciences in a research note on Friday, December 29th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of Tyra Biosciences in a research note on Tuesday, December 26th.
Tyra Biosciences Stock Up 5.4 %
Insider Activity at Tyra Biosciences
In other Tyra Biosciences news, COO Daniel Bensen sold 9,587 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $18.09, for a total value of $173,428.83. Following the completion of the transaction, the chief operating officer now owns 452,981 shares of the company’s stock, valued at approximately $8,194,426.29. The transaction was disclosed in a filing with the SEC, which is available through this link. 18.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Tyra Biosciences
Institutional investors have recently made changes to their positions in the business. Simplex Trading LLC boosted its stake in shares of Tyra Biosciences by 198.1% in the 3rd quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock valued at $27,000 after purchasing an additional 1,335 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $39,000. Driehaus Capital Management LLC grew its position in Tyra Biosciences by 12.1% during the 2nd quarter. Driehaus Capital Management LLC now owns 150,468 shares of the company’s stock valued at $2,562,000 after purchasing an additional 16,295 shares during the last quarter. Bank of New York Mellon Corp grew its position in Tyra Biosciences by 2.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 41,870 shares of the company’s stock valued at $577,000 after purchasing an additional 1,074 shares during the last quarter. Finally, UBS Group AG grew its position in Tyra Biosciences by 3,841.8% during the 4th quarter. UBS Group AG now owns 3,587 shares of the company’s stock valued at $27,000 after purchasing an additional 3,496 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Tyra Biosciences Company Profile
Tyra Biosciences, Inc, a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies.
- Five stocks we like better than Tyra Biosciences
- Your Comprehensive Guide to Investing in Bank Stocks
- 3 attractive stocks that insiders are buying
- The “How” and “Why” of Investing in 5G Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- ETF Screener: Uses and Step-by-Step Guide
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.